Literature DB >> 16618209

Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells.

Richard E Sobel1, Yuzhuo Wang, Marianne D Sadar.   

Abstract

Adenocarcinoma of the prostate comprises 95% of all prostate cancer. Commercially available primary cultures of "normal" prostate epithelial cells, PrECs, have been used as a convenient model to investigate neoplastic transformation. Here PrECs were characterized for the expression of lineage- and developmental-specific markers cytokeratin (CK) 8 and 18, p63, chromogranin A, TMEPAI, S100P, NKX 3.1, ANKH, and FN 1 as well as androgen receptor and prostate-specific antigen by Western blot and Northern blot analyses, immunohistochemistry, reverse transcriptase-polymerase chain reaction (RT-PCR), and quantitative real-time PCR. Immunohistochemical staining detected PrECs positive in varying degrees for p63, CK 8, and CK 18, with only the rare cell being positive for chromogranin A. The PrECs also tested positive for p63 protein by Western blot analysis. RT-PCR with PrEC cDNA showed products for FN 1 and S100P but not for ANKH and androgen receptor or prostate-specific antigen. This profile of markers in PrEC cells is consistent with that expected for pubertal prostate epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618209     DOI: 10.1007/s11626-006-0009-7

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  40 in total

1.  Programmed Cell Death (Apoptosis) and Cancer Chemotherapy.

Authors: 
Journal:  Cancer Control       Date:  1996-07       Impact factor: 3.302

2.  Prostate-specific and androgen-dependent expression of a novel homeobox gene.

Authors:  C J Bieberich; K Fujita; W W He; G Jay
Journal:  J Biol Chem       Date:  1996-12-13       Impact factor: 5.157

3.  The LNCaP cell line--a new model for studies on human prostatic carcinoma.

Authors:  J S Horoszewicz; S S Leong; T M Chu; Z L Wajsman; M Friedman; L Papsidero; U Kim; L S Chai; S Kakati; S K Arya; A A Sandberg
Journal:  Prog Clin Biol Res       Date:  1980

Review 4.  Primary cell cultures as models of prostate cancer development.

Authors:  D M Peehl
Journal:  Endocr Relat Cancer       Date:  2005-03       Impact factor: 5.678

5.  Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP.

Authors:  C Y Young; B T Montgomery; P E Andrews; S D Qui; D L Bilhartz; D J Tindall
Journal:  Cancer Res       Date:  1991-07-15       Impact factor: 12.701

6.  Isolation and androgen regulation of the human homeobox cDNA, NKX3.1.

Authors:  J L Prescott; L Blok; D J Tindall
Journal:  Prostate       Date:  1998-04-01       Impact factor: 4.104

7.  The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue.

Authors:  S Y Nakada; P A di Sant'Agnese; R A Moynes; R A Hiipakka; S Liao; A T Cockett; P A Abrahamsson
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

8.  Do neuroendocrine cells in human prostate cancer express androgen receptor?

Authors:  J L Krijnen; P J Janssen; J A Ruizeveld de Winter; H van Krimpen; F H Schröder; T H van der Kwast
Journal:  Histochemistry       Date:  1993-11

9.  Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer.

Authors:  Annet Hammacher; Erik W Thompson; Elizabeth D Williams
Journal:  Int J Biochem Cell Biol       Date:  2005-02       Impact factor: 5.085

10.  An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.

Authors:  Christina Voelkel-Johnson
Journal:  Cancer Biol Ther       Date:  2003 May-Jun       Impact factor: 4.742

View more
  6 in total

1.  Thioredoxin 1 as a subcellular biomarker of redox imbalance in human prostate cancer progression.

Authors:  Weihua Shan; Weixiong Zhong; Rui Zhao; Terry D Oberley
Journal:  Free Radic Biol Med       Date:  2010-10-16       Impact factor: 7.376

2.  β4 Integrin signaling induces expansion of prostate tumor progenitors.

Authors:  Toshiaki Yoshioka; Javier Otero; Yu Chen; Young-Mi Kim; Jason A Koutcher; Jaya Satagopan; Victor Reuter; Brett Carver; Elisa de Stanchina; Katsuhiko Enomoto; Norman M Greenberg; Peter T Scardino; Howard I Scher; Charles L Sawyers; Filippo G Giancotti
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

3.  The current state of preclinical prostate cancer animal models.

Authors:  Kenneth J Pienta; Cory Abate-Shen; David B Agus; Ricardo M Attar; Leland W K Chung; Norman M Greenberg; William C Hahn; John T Isaacs; Nora M Navone; Donna M Peehl; Jonathon W Simons; David B Solit; Howard R Soule; Terry A VanDyke; Michael J Weber; Lily Wu; Robert L Vessella
Journal:  Prostate       Date:  2008-05-01       Impact factor: 4.104

4.  TM4SF3 and AR: A Nuclear Complex that Stabilizes Both Proteins.

Authors:  Meenakshi Bhansali; Jun Zhou; Lirim Shemshedini
Journal:  Mol Endocrinol       Date:  2015-12-09

5.  Repression of androgen receptor transcription through the E2F1/DNMT1 axis.

Authors:  Conrad David Valdez; Joanne N Davis; Hana M Odeh; Tristan L Layfield; Craig S Cousineau; Thomas R Berton; David G Johnson; Kirk J Wojno; Mark L Day
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

6.  Distinct roles for the RNA-binding protein Staufen1 in prostate cancer.

Authors:  Kristen A Marcellus; Tara E Crawford Parks; Shekoufeh Almasi; Bernard J Jasmin
Journal:  BMC Cancer       Date:  2021-02-04       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.